<DOC>
	<DOCNO>NCT01408121</DOCNO>
	<brief_summary>This genetic platelet reactivity study African-American versus Caucasian patient undergo percutaneous coronary intervention receive clopidogrel prasugrel . The investigator aim twofold : describe difference allele frequency African-Americans Caucasians , explore association platelet reactivity genetic polymorphism two group .</brief_summary>
	<brief_title>African-American Pharmacogenetics</brief_title>
	<detailed_description>The investigator propose pharmacogenetic cohort study 100 African-American versus 100 Caucasian patient present acute coronary syndrome , receive clopidogrel prasugrel undergo PCI . The study four arm : African-American clopidogrel ; African-American prasugrel ; Caucasian clopidogrel ; Caucasian prasugrel . All patient undergo genotyping platelet reactivity test VerifyNow P2Y12 assay , least 6 hour receive thienopyridine load dose , hospital discharge . All patient treat aspirin 325 mg/day well . Race determination base patient 's self-report , patient enrol trial must also report four grandparent race . Other race ( Asian , Native American , et al ) exclude study .</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>1 . Patients age 18 old , gender 2 . Presenting ACS , define least two follow : symptom consistent myocardial ischemia ; ST segment elevation depression least 1 mm 2 contiguous lead EKG ; cardiac troponin I level upper limit normal . 3 . Selfreported Africanamerican Caucasian race a. 4 grandparent race 4 . No contraindication prasugrel therapy . 5 . Patient schedule , already undergone , PCI . 1 . Known allergy aspirin , clopidogrel , prasugrel . 2 . Patient know pregnant lactating . 3 . Patient known history bleed diathesis currently active bleeding . 4 . Platelet count &lt; 100,000/mm time enrollment . 5 . Hematocrit &lt; 25 % time enrollment . 6 . On warfarin therapy time PCI , patient likely require warfarin therapy postPCI . 7 . Received fibrinolytics within past 48 hour . 8 . Received glycoprotein IIb/IIIa inhibitor within past 48 hour , strategy PCI involve glycoprotein IIb/IIIa inhibitor plan . 9 . Taking maintenance thienopyridine therapy previous 5 day . 10 . Known blood transfusion within precede 10 day . 11 . Patients treat nonsteroidal antiinflammatory drug ( NSAIDS ) within previous 5 day . 12 . Patients know chronic liver disease . 13 . Age great 75 year 14 . Body weight less 60 kg 15 . History stroke transient ischemic attack 16 . Surgery plan within 1 month 17 . Patient likely require coronary artery bypass graft 18 . Any significant medical condition , investigator 's opinion , may interfere patient 's optimal participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Platelet reactivity</keyword>
	<keyword>Genotyping</keyword>
</DOC>